Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Sheikh

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Radiologie (Heidelberg, Germany)|May 7, 2024
[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology]R Ebner, J Rübenthaler, J Ricke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA-therapyGabriel T Sheikh, Sophie C Siegmund, Liam Widjaja, et al.
EJNMMI Research|March 4, 2025
RECIP 1.0 + PSA for response assessment in mCRPC patients treated with <sup>225</sup>Ac / <sup>177</sup>Lu PSMA combination therapyGabriel T Sheikh, Astrid Delker, Mathias J Zacherl, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Molecular Imaging and Biology|September 30, 2025
Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid CarcinomaSophie Carina Kunte, Vera U Wenter, Adrien Holzgreve, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 5, 2025
Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor-related pneumonitis in lung cancer patientsFriederike Völter, Lukas Wehlte, Blerina Resuli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 1, 2025
Refining the clinical utility of [<sup>177</sup>Lu]Lu/[<sup>225</sup>Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancerLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
EJNMMI Physics|February 9, 2023
Investigation of image-based lesion and kidney dosimetry protocols for <sup>177</sup>Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisitionSandra Resch, Sarah Takayama Fouladgar, Mathias Zacherl, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Radiologie (Heidelberg, Germany)|May 7, 2024
[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology]R Ebner, J Rübenthaler, J Ricke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA-therapyGabriel T Sheikh, Sophie C Siegmund, Liam Widjaja, et al.
EJNMMI Research|March 4, 2025
RECIP 1.0 + PSA for response assessment in mCRPC patients treated with <sup>225</sup>Ac / <sup>177</sup>Lu PSMA combination therapyGabriel T Sheikh, Astrid Delker, Mathias J Zacherl, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Molecular Imaging and Biology|September 30, 2025
Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid CarcinomaSophie Carina Kunte, Vera U Wenter, Adrien Holzgreve, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 5, 2025
Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor-related pneumonitis in lung cancer patientsFriederike Völter, Lukas Wehlte, Blerina Resuli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 1, 2025
Refining the clinical utility of [<sup>177</sup>Lu]Lu/[<sup>225</sup>Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancerLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
EJNMMI Physics|February 9, 2023
Investigation of image-based lesion and kidney dosimetry protocols for <sup>177</sup>Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisitionSandra Resch, Sarah Takayama Fouladgar, Mathias Zacherl, et al.
Pageof 6